|
Market Closed -
Japan Exchange
01:30:00 2026-01-16 EST
|
5-day change
|
1st Jan Change
|
|
5,073.00 JPY
|
-1.99%
|
 |
-0.14%
|
+4.92%
|
|
11-11 |
Neurocrine Biosciences' Depressive Disorder Drug Fails to Meet Primary Goal in Phase 2 Study
|
MT
| |
25-09-26 |
Alkermes' Stock Dip on Narcolepsy Data Seen as Buying Opportunity, RBC Says
|
MT
| |
25-08-20 |
Veeva Systems Q2 Results Likely In-Line to Better, Maintain H2 Outlook, Truist Says
|
MT
| |
25-05-09 |
Jefferies Adjusts Takeda Pharmaceutical's Price Target to 5,100 Yen From 5,500 Yen, Keeps at Buy
|
MT
| |
25-05-06 |
Jefferies Adjusts Takeda Pharmaceutical Company's Price Target to 5,500 Yen From 5,000 Yen, Keeps at Buy
|
MT
| |
24-08-12 |
Jefferies Adjusts Takeda Pharmaceutical's Price Target to 5,000 Yen From 4,800 Yen, Keeps at Buy
|
MT
| |
24-07-31 |
Jefferies Adjusts Takeda Pharmaceutical's Price Target to 4,800 Yen From 5,600 Yen, Keeps at Buy
|
MT
| |
24-02-13 |
Jefferies Adjusts Takeda Pharmaceutical's Price Target to 5,600 Yen From 5,200 Yen, Keeps at Buy
|
MT
| |
23-10-03 |
Jefferies Adjusts Takeda Pharmaceutical’s Price Target to 5,200 Yen From 5,300 Yen, Keeps at Buy
|
MT
| |
23-09-22 |
Jefferies Adjusts Takeda Pharmaceutical’s Price Target to 5,300 Yen From 5,100 Yen, Keeps at Buy
|
MT
| |
23-05-31 |
Jefferies Adjusts Takeda Pharmaceutical’s Price Target to 5,100 Yen From 5,000 Yen, Keeps at Buy
|
MT
| |
23-05-16 |
TD Cowen Adjusts Price Target on Takeda Pharmaceutical to $20 From $30, Maintains Outperform Rating
|
MT
| |
23-04-04 |
TD Cowen Adjusts Price Target on Takeda Pharmaceutical to $30 From $24, Keeps Outperform Rating
|
MT
| |
23-03-23 |
Japanese shares hover near session high on hints of Fed rate pause
|
RE
| |
23-03-16 |
BofA Securities Upgrades Takeda Pharmaceutical to Buy From Neutral, Price Target $20
|
MT
| |
23-03-06 |
Jefferies Adjusts Takeda Pharmaceutical’s Price Target to 5,000 Yen From 4,600 Yen, Keeps at Buy
|
MT
| |
22-08-01 |
Jefferies Downgrades Takeda Pharmaceutical to Hold From Buy
|
MT
| |
22-07-19 |
Cowen Upgrades Takeda Pharmaceutical to Outperform From Market Perform
|
MT
| |
21-10-07 |
TAKEDA PHARMACEUTICAL : Morgan Stanley Downgrades Takeda Pharmaceutical to Equal-weight From Overweight
|
MT
| |
21-05-31 |
Takeda Pharmaceutical : Japanese shares inch down as investors await key U.S. economic data
|
RE
| |
17-09-08 |
BAYER : Germany's Merck hires JP Morgan to sell consumer health
|
RE
|
No results for this search Select your edition All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
| 
